ライフサイエンスコーパス: chemotherapeutic agent

1 rosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent).

2 timuli (for example, nutrient starvation and chemotherapeutic agents).

3 +) tumor targets even in the presence of the chemotherapeutic agent.

4 d CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent.

5 rscoring the compound's potential as a novel chemotherapeutic agent.

6 al acne creams as well as being a first-line chemotherapeutic agent.

7 taxel, an important yet poorly water-soluble chemotherapeutic agent.

8 to reduce pain in patients treated with this chemotherapeutic agent.

9 tion with temozolomide, the standard-of-care chemotherapeutic agent.

10 by death receptors or intrinsic apoptosis by chemotherapeutic agents.

11 n of apical ballooning syndrome with various chemotherapeutic agents.

12 -specific delivery of appropriately designed chemotherapeutic agents.

13 r, is largely resistant to many conventional chemotherapeutic agents.

14 major pathway of apoptosis induction by many chemotherapeutic agents.

15 veruse and misuse of clinical and veterinary chemotherapeutic agents.

16 g resistance based on the cellular efflux of chemotherapeutic agents.

17 nd protects against cell stressors including chemotherapeutic agents.

18 ng the potential toxicity of other cytotoxic chemotherapeutic agents.

19 drugs, including peptides, antibiotics, and chemotherapeutic agents.

20 rwise sublethal doses of clinically relevant chemotherapeutic agents.

21 and are highly tumorigenic and resistant to chemotherapeutic agents.

22 ous metabolites and some commonly prescribed chemotherapeutic agents.

23 to glucocorticoid agonists, but not to other chemotherapeutic agents.

24 It also informs the choice of chemotherapeutic agents.

25 t Jurkat cells during apoptotic responses to chemotherapeutic agents.

26 wal by serial passages of hepatospheres with chemotherapeutic agents.

27 urvival pathways and conferred resistance to chemotherapeutic agents.

28 iple myeloma cells from apoptosis induced by chemotherapeutic agents.

29 lls, thus improving the therapeutic index of chemotherapeutic agents.

30 nd are the targets of several antibiotic and chemotherapeutic agents.

31 l drug, drives the search for new classes of chemotherapeutic agents.

32 st 20 years despite the development of novel chemotherapeutic agents.

33 ncer drug to overcome limitations of current chemotherapeutic agents.

34 afforded greater protection against several chemotherapeutic agents.

35 ic target, thus eliminating the need for any chemotherapeutic agents.

36 apable of engrafting immunodeficient mice by chemotherapeutic agents.

37 is as well as the antitumor activity of many chemotherapeutic agents.

38 cell death, undermining the effectiveness of chemotherapeutic agents.

39 icrotubule poisons, including currently used chemotherapeutic agents.

40 rapidly develops resistance to a variety of chemotherapeutic agents.

41 attractive target for new parasite-specific chemotherapeutic agents.

42 detection of cellular changes in response to chemotherapeutic agents.

43 s and pathomechanisms of specific neurotoxic chemotherapeutic agents.

44 alein are attractive candidates for improved chemotherapeutic agents.

45 lf-life and toxicity related side effects of chemotherapeutic agents.

46 d to potentiate the efficacy of conventional chemotherapeutic agents.

47 GCS-100 rendered DLBCL cells susceptible to chemotherapeutic agents.

48 e as a defensive shield against conventional chemotherapeutic agents.

49 ry and academia towards the discovery of new chemotherapeutic agents.

50 ion with other tyrosine kinase inhibitors or chemotherapeutic agents.

51 that together cause inefficient delivery of chemotherapeutic agents.

52 dose-limiting side effect of many important chemotherapeutic agents.

53 DNA breaks caused by ionizing radiation and chemotherapeutic agents.

54 tic alterations or to screen the efficacy of chemotherapeutic agents.

55 nsitization of HCC cells toward conventional chemotherapeutic agents.

56 iology of cancer cells and their response to chemotherapeutic agents.

57 chanism to stress, including that induced by chemotherapeutic agents.

58 ing the brain against the effects of various chemotherapeutic agents.

59 Cs accounts for positive immunomodulation by chemotherapeutic agents.

60 y and can ultimately improve the efficacy of chemotherapeutic agents.

61 rs cytoprotection against stress stimuli and chemotherapeutic agents.

62 tumor growth, and enhance susceptibility to chemotherapeutic agents.

63 Moreover, treatment with the chemotherapeutic agent 5-fluorouracil (5-FU) also induce

64 gher resistance to serial treatment with the chemotherapeutic agent 5-fluorouracil (5-FU).

65 duces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil.

66 ion, and resistance to the colorectal cancer chemotherapeutic agent 5-fluorouracil.

67 astuzumab and pertuzumab became resistant to chemotherapeutic agents (5-fluoruracil, carboplatin, cis

68 ployed as an inhibitor of DNA methylation, a chemotherapeutic agent, a clastogen, a mutagen, an induc

69 Thus, ATF3 in the host cells links a chemotherapeutic agent-a stressor-to immune modulation a

70 We also found that commonly used cytotoxic chemotherapeutic agents activate HHV replication, which

71 coming drug formulation to be evaluated as a chemotherapeutic agent against malignant melanoma.

72 d its analogs are among the most widely used chemotherapeutic agents against various types of cancer.

73 When compared with the chemotherapeutic agent alone, knockdown of the correspon

74 opoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduce

75 ng the use of olaparib in combination with a chemotherapeutic agent and provides a foundation for fut

76 Cladribine was the most commonly used chemotherapeutic agent and was administered in 21 of 63

77 EPO stimulation increased BCSC resistance to chemotherapeutic agents and activated cellular pathways

78 the past four decades because of advances in chemotherapeutic agents and administration protocols as

79 vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipul

80 combinations of conventional small molecule chemotherapeutic agents and biologics.

81 ls (BMDCs), we exposed tumor-bearing mice to chemotherapeutic agents and evaluated the influx and con

82 that Nrf2 may also protect cancer cells from chemotherapeutic agents and facilitate cancer progressio

83 They showed markedly increased resistance to chemotherapeutic agents and hypoxic injury.

84 s BAK activation in tumor cells treated with chemotherapeutic agents and is associated with increased

85 To overcome such barriers, a number of chemotherapeutic agents and nucleic acid-based therapies

86 are caused by environmental, endogenous, and chemotherapeutic agents and pose a severe threat to geno

87 ) confers resistance to standard-of-care MCC chemotherapeutic agents and provide proof-of-principle t

88 ted a possible association between different chemotherapeutic agents and PVOD.

89 We evaluated the relationship between chemotherapeutic agents and PVOD.

90 exhibited distinct sensitivities toward drug chemotherapeutic agents and radiation as compared with t

91 Besides chemotherapeutic agents and radiation therapy, approache

92 ells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after the

93 CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk.

94 our cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, includin

95 erentiation, reversed resistance to multiple chemotherapeutic agents, and impaired tumor growth in vi

96 hibited reduced proliferation, resistance to chemotherapeutic agents, and stem-like metabolic changes

97 chemoresistance in the AML cells exposed to chemotherapeutic agents, and this was reversed following

98 motherapy resistance, optimizing efficacy of chemotherapeutic agents, antiangiogenic effects, and alt

99 Paclitaxel (PTX) is one of the most useful chemotherapeutic agents approved for several cancers, in

100 rodegenerative changes and a number of newer chemotherapeutic agents are being tested to ameliorate t

101 Most chemotherapeutic agents are blood-brain barrier (BBB) im

102 rapy markedly alters memory processes, while chemotherapeutic agents are correlated with deficits in

103 cancers are highly sensitive to ICL-inducing chemotherapeutic agents, are amenable to synthetic letha

104 Asparaginase, a widely used chemotherapeutic agent, arrests GAS growth in human bloo

105 ed the predictive value of the assay against chemotherapeutic agents as well as environmental compoun

106 esorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximate

107 spindle poisons are among the most important chemotherapeutic agents available.

108 efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on a CD33 antibody.

109 as adherent cultures, and sensitivity to the chemotherapeutic agent BCNU.

110 Cisplatin is a particularly potent chemotherapeutic agent, but its use to treat GBM is limi

111 ter membrane that would prevent the entry of chemotherapeutic agents, but this could not be tested be

112 gold salt auranofin and the investigational chemotherapeutic agent buthionione sulfoximine (BSO).

113 also improved in vitro NSCLC sensitivity to chemotherapeutic agents by promoting apoptosis.

114 Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibi

115 However, as chemotherapeutic agents can affect the central and perip

116 ironmental exposure, and treatment with some chemotherapeutic agents can all give rise to DNA alkylat

117 atment of cancer cells with the FDA-approved chemotherapeutic agent carboplatin induced autophagy and

118 he anthracycline doxorubicin (Dox) and other chemotherapeutic agents causes irreversible cardiac dama

119 Chemotherapeutic agents (ChAs) are considered an integra

120 ass of DNA adducts formed by the widely used chemotherapeutic agent cis-diamminedichloroplatinum (cis

121 excision repair of DNA damage caused by the chemotherapeutic agent cisplatin and, in certain genetic

122 ficacious and well-established anthracycline chemotherapeutic agent commonly used in the treatment of

123 f male mice treated with three commonly used chemotherapeutic agents: cyclophosphamide, mitomycin C,

124 Our results reveal a mechanism through which chemotherapeutic agents damage rapidly proliferating epi

125 evented peripheral neuropathy induced by the chemotherapeutic agents dichloroacetate and paclitaxel o

126 Because most chemotherapeutic agents do not effectively cross the blo

127 id not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX) in a xenograft

128 poly (beta-amino ester) (PBAE) copolymer, a chemotherapeutic agent doxorubicin (DOX).

129 nd on the sensitivity of cancer cells to the chemotherapeutic agent doxorubicin (DXR) and growth fact

130 Clinical use of the widely used chemotherapeutic agent doxorubicin is limited by life-th

131 drugs, possibly allowing a reduction of the chemotherapeutic agent effective dose.

132 Doxorubicin (DOX) is a chemotherapeutic agent effective in the treatment of man

133 BNPs loaded with a potent chemotherapeutic agent [epothilone B (EB)] showed signif

134 2)-DNA adducts induced by treatment with the chemotherapeutic agent etoposide.

135 that mammalian cell lines resistant to other chemotherapeutic agents exhibit only modest resistance,

136 ABT-869 and chemotherapeutic agents exhibited a strong synergy to in

137 f solid tumors and describes the infusion of chemotherapeutic agents followed by embolization with pa

138 bitor bortezomib, proposed as an alternative chemotherapeutic agent for both primary and cisplatin-re

139 s the potential to be developed further as a chemotherapeutic agent for CRC.

140 ycle arrest and highlight its potential as a chemotherapeutic agent for HNSCC.

141 Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors

142 cal evaluation of compound 12 as a potential chemotherapeutic agent for TNBC and cancers with constit

143 -of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum

144 Malaria control is heavily dependent on chemotherapeutic agents for disease prevention and drug

145 tams derived from 4-aminoquinoline as potent chemotherapeutic agents for malaria treatment.

146 cell survival, which leads to new candidate chemotherapeutic agents for neoplastic disease.

147 oint kinase inhibitors with the DNA-damaging chemotherapeutic agent gemcitabine offers clinical appea

148 st), as well as pharmacologic assays against chemotherapeutic agents (half-maximal effective concentr

149 hat produces a slow and sustained release of chemotherapeutic agent, has recently been shown to have

150 anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overa

151 Several chemotherapeutic agents have been reported to induce sub

152 Most recently, other chemotherapeutic agents have been tried for OSSN includi

153 Chemotherapeutic agents have certain limitations when it

154 AML, whereas more novel and potent cytotoxic chemotherapeutic agents hold promise and are entering th

155 uccess has been achieved with platinum-based chemotherapeutic agents, i.e. through interactions with

156 ificantly higher sensitivity to the standard chemotherapeutic agents, i.e., doxorubicin (DOX) and cyt

157 Doxorubicin (DOX), a common chemotherapeutic agent, impairs synaptic plasticity.

158 After the approval of cisplatin as a chemotherapeutic agent in 1978, several types of metal-b

159 ets of glioma cells to a clinically relevant chemotherapeutic agent in the same well in culture or an

160 y, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its abil

161 at the mitochondrion ("priming") induced by chemotherapeutic agents in cancer cells, not requiring p

162 Thiopurine drugs are extensively used as chemotherapeutic agents in clinical practice, even thoug

163 ression promotes cellular resistance towards chemotherapeutic agents in cultured CRC cells and colore

164 Lumican secretion was increased by chemotherapeutic agents in PDAC, and especially in PSCs,

165 at sustained exposure of microtubule-binding chemotherapeutic agents in peripheral nerve tissues cann

166 e research to achieve better optimization of chemotherapeutic agents in the elderly.

167 estigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen.

168 ave important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexp

169 ituximab (RTX), alone or in combination with chemotherapeutic agents in unmanipulated whole blood ass

170 clinically achievable doses of HRR-inducing chemotherapeutic agents in vitro and in vivo in a murine

171 DGFRs sensitizes mammary epithelial cells to chemotherapeutic agents in vitro and in vivo.

172 n of mutant K-Ras cancer cells to DNA damage chemotherapeutic agents in vitro and in vivo.

173 a cell migration, invasion and resistance to chemotherapeutic agents in vitro.

174 However, insensitivity to these chemotherapeutic agents including cisplatin is common.

175 nergistic therapeutic effects with different chemotherapeutic agents including doxorubicin, l-asparag

176 tor contributing to variation in response to chemotherapeutic agents including gemcitabine, a first l

177 ion of those MDR tumor cells to conventional chemotherapeutic agents, including cisplatin, sorafenib,

178 Several chemotherapeutic agents, including paclitaxel (Taxol), i

179 ently, it is the target of several antitumor chemotherapeutic agents, including the AR antagonist MDV

180 r than 3 g/dL, and receipt of no more than 2 chemotherapeutic agents independently predicted better s

181 Chemotherapeutic agents induce complex tissue responses

182 otherapy in PDAC cells through inhibition of chemotherapeutic agent-induced autophagy.

183 dy we demonstrated that HSF1 is required for chemotherapeutic agent-induced cytoprotective autophagy

184 Identification of novel drug targets and chemotherapeutic agents is a high priority in the fight

185 r, the efficacy of nanoparticles loaded with chemotherapeutic agents is currently hampered by their f

186 nt on the development of resistance to other chemotherapeutic agents is unknown.

187 Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute an

188 Doxorubicin, a common chemotherapeutic agent, is known to promote PML-mediated

189 Although chemotherapeutic agents kill cancer cells, these treatme

190 various cancers, promote the elimination of chemotherapeutic agents, leading to reduced therapeutic

191 Additionally, the combination of ABT-869 and chemotherapeutic agents led to remarkable suppression of

192 s inhibitors (median RR, 3.39; P < .001) and chemotherapeutic agents (median RR, 1.73; P < .001), wer

193 Isolated limb perfusion (ILP) with the chemotherapeutic agent melphalan is an effective treatme

194 mall intestinal tissue damage induced by the chemotherapeutic agent methotrexate.

195 the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than p

196 -7 cells and sensitized the MDR cells to the chemotherapeutic agent mitoxantrone (MX); combination tr

197 e results showed that MSNR could deliver the chemotherapeutic agent, MTX to tumor cells and induce ef

198 requency either alone or in combination with chemotherapeutic agents, namely, cisplatin, docetaxel, a

199 However, in spite of effective chemotherapeutic agents, neuropathy and associated defor

200 Docetaxel is a chemotherapeutic agent of the taxane class of drugs for

201 Targeted chemotherapeutic agents often do not result in tumor shr

202 O administration counteracted the effects of chemotherapeutic agents on BCSC-derived orthotopic tumor

203 The present study evaluated the effect of chemotherapeutic agents on exosome production and/or rel

204 del, we demonstrate increased sensitivity to chemotherapeutic agents on reduction of Evi1 expression.

205 To study the effects of chemotherapeutic agents on the hair follicle, a number o

206 Lastly, we determined the efficacy of chemotherapeutic agents on TMF by impedance spectroscopy

207 th a favorable toxicity profile, either as a chemotherapeutic agent or a radiosensitizer.

208 gration and survival of cells in response to chemotherapeutic agents or withdrawal of glucose.

209 carcinoma cells and sensitized cells toward chemotherapeutic agents or X-ray irradiation.

210 Infusion of the chemotherapeutic agent oxaliplatin leads to an acute and

211 contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX).

212 d heat stimulation) or by treatment with the chemotherapeutic agent paclitaxel (which induces hyperse

213 c human breast cancer cells subjected to the chemotherapeutic agent paclitaxel at the single-cell and

214 nduced by complete Freund's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not C

215 Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by alter

216 The efficacy of two front-line chemotherapeutic agents (paclitaxel and cisplatin) are d

217 ouse model of toxic neuropathy produced by a chemotherapeutic agent, paclitaxel.

218 ne of the most effective and frequently used chemotherapeutic agents, paclitaxel produces peripheral

219 d disease is acquired resistance to multiple chemotherapeutic agents, particularly glucocorticoids.

220 indicates that cancer cell stress induced by chemotherapeutic agents promote antitumor immune respons

221 HSP70-targeted therapy (but not chemotherapeutic agents) promoted apoptosis in RMS cells

222 ill summarize the immune effects of selected chemotherapeutic agents, radiotherapy and recent results

223 ological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to suc

224 ncers (MDR) and attendant resensitization to chemotherapeutic agents represent a promising strategy f

225 his unidirectional transfer enhanced by some chemotherapeutic agents required cell-cell contacts and

226 oncurrent exposure of cells to dasatinib and chemotherapeutic agents resulted in additive effects.

227 ng the capability to design a Rac1-targeting chemotherapeutic agent(s) for autoimmune disorders.

228 grapefruit-derived nanovectors, can deliver chemotherapeutic agents, short interfering RNA, DNA expr

229 Specifically, the chemotherapeutic agent SN-38 is incorporated into a cent

230 e ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).

231 Our results indicate (a) chemotherapeutic agents stimulate exosome production or

232 Thus, proapoptotic chemotherapeutic agents stimulate the caspase-8-mediated

233 Classical chemotherapeutic agents such as cisplatin, often used in

234 sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and et

235 imulated with TLR4 agonists and proapoptotic chemotherapeutic agents such as doxorubicin (Dox) or sta

236 larly when used in combination with selected chemotherapeutic agents such as oxaliplatin.

237 Anti-mitotic chemotherapeutic agents such as taxanes activate the spi

238 NEC has increased with the widespread use of chemotherapeutic agents such as the taxanes, which cause

239 stance to genotoxic stress induced by common chemotherapeutic agents, such as cis-diammine-dichloropl

240 rescue pol beta-deficient cells treated with chemotherapeutic agents suggesting that these agents may

241 ors, co-delivery of survivin inhibitors with chemotherapeutic agents, synchronous targeting of surviv

242 tion of a PARP1 inhibitor to the second-line chemotherapeutic agent temozolamide resulted in complete

243 ance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to c

244 erapeutic effect was relatively unique among chemotherapeutic agents tested, suggesting distinctive e

245 ithiothymine can act as a more effective UVA chemotherapeutic agent than the currently used 4-thiothy

246 in EpCAM(+) spheroids are more resistant to chemotherapeutic agents than 2D-cultured cells.

247 Drosophila larvae with paclitaxel (taxol), a chemotherapeutic agent that causes neuropathy in cancer

248 Here we focus on oxaliplatin, an immunogenic chemotherapeutic agent that is effective in aggressive p

249 3, and 5 after treatment with gemcitabine, a chemotherapeutic agent that is powerfully myelosuppressi

250 Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that is widely used in cancer tre

251 ABT-737 is a promising chemotherapeutic agent that promotes apoptosis by acting

252 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides additional survival

253 t to DNA damage from the immune response and chemotherapeutic agents that can significantly disrupt g

254 These findings advocate development of chemotherapeutic agents that cause fewer long-term side

255 In mouse hair follicles, those chemotherapeutic agents that disrupted feather formation

256 human cancer cells the ability to counteract chemotherapeutic agents that elicit cell death by damagi

257 ture call attention to gemcitabine and other chemotherapeutic agents that have been reported to cause

258 , which would be an improvement over current chemotherapeutic agents that indiscriminately kill proli

259 y to sensitize breast and ovarian cancers to chemotherapeutic agents that induce DNA damage.

260 d to antimicrobial resistance but also to be chemotherapeutic agents that may be allergenic and poten

261 When subject to a spatial gradient of a chemotherapeutic agent, the cells in the middle of the s

262 ular target to increase, in combination with chemotherapeutic agents, the sensitivity of treatment, e

263 adiation, more recent studies have relied on chemotherapeutic agents to induce apoptosis in cell line

264 The ability of chemotherapeutic agents to induce apoptosis, predominant

265 n multiple animal models and cooperates with chemotherapeutic agents to reduce cancer cell survival.

266 ul method for an effective local delivery of chemotherapeutic agents to treatment of cancers.

267 geted carriers provide efficient delivery of chemotherapeutic agents to tumor tissue.

268 the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mous

269 In PDAC cells, chemotherapeutic agents triggered autophagosome formatio

270 tumor cells by extruding a broad variety of chemotherapeutic agents, ultimately leading to failure o

271 -dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of car

272 s have similar sensitivities to cisplatin, a chemotherapeutic agent used in the treatment of MM.

273 ow show that temozolomide (TMZ), a principal chemotherapeutic agent used to treat GBM, increases the

274 in tumor cells in response to doxorubicin, a chemotherapeutic agent used to treat many cancers.

275 may also be involved in resistance to other chemotherapeutic agents used in the treatment of multipl

276 A enzymes metabolize endogenous hormones and chemotherapeutic agents used to treat cancer, thereby po

277 zymes sensitize lung adenocarcinoma cells to chemotherapeutic agents via induction of mitochondrial d

278 n a mouse model of neuropathy induced by the chemotherapeutic agent vincristine.

279 The chemotherapeutic agent vinorelbine increased apoptosis o

280 ose-limiting side effect of many widely used chemotherapeutic agents.We demonstrate that the developm

281 tentiating effects of Wip1 overexpression on chemotherapeutic agents were directed only to tumor cell

282 A number of DNA-binding chemotherapeutic agents were found to non-specifically d

283 Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel

284 chemotherapy, and intraocular injections of chemotherapeutic agents were successfully introduced.

285 Mitomycin and platinum-based chemotherapeutic agents were used in 96 (72.2%) and 37 (

286 ving a morphological record of the impact of chemotherapeutic agents, whereas the rachis (feather axi

287 t a new approach to maximize the efficacy of chemotherapeutic agents while reducing dose-related toxi

288 nal antibody to increase the efficacy of the chemotherapeutic agent, while reducing toxicity.

289 Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent a

290 Daunomycin (DUN), a chemotherapeutic agent with autofluorescence, was used t

291 rsenic trioxide (As(2)O(3)), an FDA-approved chemotherapeutic agent with known effects on several oth

292 Y-I2-BODIPY can act as an immune-stimulatory chemotherapeutic agent with potential applications in cl

293 These findings strongly argue that combining chemotherapeutic agents with autophagy inhibition by rep

294 rveillance by tuning down autophagy, certain chemotherapeutic agents with immunogenic properties may

295 opment of more effective chemopreventive and chemotherapeutic agents with less toxicity.

296 Chemotherapeutic agents with low toxicity to normal tiss

297 last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the int

298 rs an attractive route of administration for chemotherapeutic agents, with the advantages of high dru

299 Sec61beta modulates the cytotoxicity of many chemotherapeutic agents, with the largest effect being o

300 Cisplatin is a common and effective chemotherapeutic agent, yet it often causes permanent he